<code id='1D18F7E1CE'></code><style id='1D18F7E1CE'></style>
    • <acronym id='1D18F7E1CE'></acronym>
      <center id='1D18F7E1CE'><center id='1D18F7E1CE'><tfoot id='1D18F7E1CE'></tfoot></center><abbr id='1D18F7E1CE'><dir id='1D18F7E1CE'><tfoot id='1D18F7E1CE'></tfoot><noframes id='1D18F7E1CE'>

    • <optgroup id='1D18F7E1CE'><strike id='1D18F7E1CE'><sup id='1D18F7E1CE'></sup></strike><code id='1D18F7E1CE'></code></optgroup>
        1. <b id='1D18F7E1CE'><label id='1D18F7E1CE'><select id='1D18F7E1CE'><dt id='1D18F7E1CE'><span id='1D18F7E1CE'></span></dt></select></label></b><u id='1D18F7E1CE'></u>
          <i id='1D18F7E1CE'><strike id='1D18F7E1CE'><tt id='1D18F7E1CE'><pre id='1D18F7E1CE'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:2

          How do cancer drugs work? What makes biotech stocks go up? And why are venture capitalists so optimistic?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe. We also discuss the latest news in the life sciences, including the future of Alzheimer’s disease treatment, a multibillion-dollar deal, and the return of the biotech mega-round.

          advertisement

          For more on what we cover, here’s STAT’s coverage of the European Society for Medical Oncology meeting; here’s more on Roivant Sciences; here’s the latest on biotech venture capital; here’s more on the latest Alzheimer’s data; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          comprehensive

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          There's no autism epidemic. It's an autism diagnosis epidemic
          There's no autism epidemic. It's an autism diagnosis epidemic

          AdobeIsthereanautismepidemic?No.TheincreaseintheautismraterecentlyreportedbytheCentersforDiseaseCont

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

          HyacinthEmpinado/STATNewbiotechnewsletterlaunchingtomorrow.Don’tmissout.Goodmorning,everyone.Damianh